These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22591915)

  • 1. [18F]desmethoxyfallypride as a novel PET radiotracer for quantitative in vivo dopamine D2/D3 receptor imaging in rat models of neurodegenerative diseases.
    Döbrössy MD; Braun F; Klein S; Garcia J; Langen KJ; Weber WA; Nikkhah G; Meyer PT
    Nucl Med Biol; 2012 Oct; 39(7):1077-80. PubMed ID: 22591915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [¹⁸F]fallypride and [¹⁸F]desmethoxyfallypride.
    Constantinescu CC; Coleman RA; Pan ML; Mukherjee J
    Synapse; 2011 Aug; 65(8):778-87. PubMed ID: 21218455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of the dopamine D2/3 receptor ligand 18F-desmethoxyfallypride for the differentiation of idiopathic and nonidiopathic parkinsonian syndromes.
    la Fougère C; Pöpperl G; Levin J; Wängler B; Böning G; Uebleis C; Cumming P; Bartenstein P; Bötzel K; Tatsch K
    J Nucl Med; 2010 Apr; 51(4):581-7. PubMed ID: 20237026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism.
    Schreckenberger M; Hägele S; Siessmeier T; Buchholz HG; Armbrust-Henrich H; Rösch F; Gründer G; Bartenstein P; Vogt T
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1128-35. PubMed ID: 15042325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deficits in striatal dopamine D(2) receptors and energy metabolism detected by in vivo microPET imaging in a rat model of Huntington's disease.
    Araujo DM; Cherry SR; Tatsukawa KJ; Toyokuni T; Kornblum HI
    Exp Neurol; 2000 Dec; 166(2):287-97. PubMed ID: 11085894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride.
    Gründer G; Siessmeier T; Piel M; Vernaleken I; Buchholz HG; Zhou Y; Hiemke C; Wong DF; Rösch F; Bartenstein P
    J Nucl Med; 2003 Jan; 44(1):109-16. PubMed ID: 12515884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of D2/D3 receptors increases efficacy of ropinirole in chronically 6-OHDA-lesioned Parkinsonian rats.
    Matsukawa N; Maki M; Yasuhara T; Hara K; Yu G; Xu L; Kim KM; Morgan JC; Sethi KD; Borlongan CV
    Brain Res; 2007 Jul; 1160():113-23. PubMed ID: 17573046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic exposure to dopamine agonists affects the integrity of striatal D
    Politis M; Wilson H; Wu K; Brooks DJ; Piccini P
    Neuroimage Clin; 2017; 16():455-460. PubMed ID: 28879087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of striatal dopamine D2/D3 receptor availability with PET and 18F-desmethoxyfallypride: comparison of imaging protocols suited for clinical routine.
    Amtage F; Spehl TS; Hellwig S; Sahm U; Hellwig B; Reuland P; Weiller C; Weber WA; Winkler C; Meyer PT
    J Nucl Med; 2012 Oct; 53(10):1558-64. PubMed ID: 22899645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous competition against binding of [(18)F]DMFP and [(18)F]fallypride to dopamine D(2/3) receptors in brain of living mouse.
    Rominger A; Wagner E; Mille E; Böning G; Esmaeilzadeh M; Wängler B; Gildehaus FJ; Nowak S; Bruche A; Tatsch K; Bartenstein P; Cumming P
    Synapse; 2010 Apr; 64(4):313-22. PubMed ID: 19957365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and evaluation in rats of the dopamine D2/3 receptor agonist 18F-AMC20 as a potential radioligand for PET.
    Shalgunov V; van Wieringen JP; Janssen HM; Fransen PM; Dierckx RA; Michel MC; Booij J; Elsinga PH
    J Nucl Med; 2015 Jan; 56(1):133-9. PubMed ID: 25476538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of alcohol craving with striatal dopamine synthesis capacity and D2/3 receptor availability: a combined [18F]DOPA and [18F]DMFP PET study in detoxified alcoholic patients.
    Heinz A; Siessmeier T; Wrase J; Buchholz HG; Gründer G; Kumakura Y; Cumming P; Schreckenberger M; Smolka MN; Rösch F; Mann K; Bartenstein P
    Am J Psychiatry; 2005 Aug; 162(8):1515-20. PubMed ID: 16055774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Food restriction markedly increases dopamine D2 receptor (D2R) in a rat model of obesity as assessed with in-vivo muPET imaging ([11C] raclopride) and in-vitro ([3H] spiperone) autoradiography.
    Thanos PK; Michaelides M; Piyis YK; Wang GJ; Volkow ND
    Synapse; 2008 Jan; 62(1):50-61. PubMed ID: 17960763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
    Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
    Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders.
    Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I
    Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compensation for cranial spill-in into the cerebellum improves quantitation of striatal dopamine D₂/₃ receptors in rats with prolonged [¹⁸F]-DMFP infusions.
    Mille E; Cumming P; Rominger A; La Fougère C; Tatsch K; Wängler B; Bartenstein P; Böning G
    Synapse; 2012 Aug; 66(8):705-13. PubMed ID: 22460766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.
    Antonini A; Leenders KL; Spiegel R; Meier D; Vontobel P; Weigell-Weber M; Sanchez-Pernaute R; de Yébenez JG; Boesiger P; Weindl A; Maguire RP
    Brain; 1996 Dec; 119 ( Pt 6)():2085-95. PubMed ID: 9010012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex.
    Häggkvist J; Tóth M; Tari L; Varnäs K; Svedberg M; Forsberg A; Nag S; Dominguez C; Munoz-Sanjuan I; Bard J; Wityak J; Varrone A; Halldin C; Mrzljak L
    J Nucl Med; 2017 Apr; 58(4):617-622. PubMed ID: 27856625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D
    Ghazanfari N; van Waarde A; Doorduin J; Sijbesma JWA; Kominia M; Koelewijn M; Attia K; Vállez-García D; Willemsen ATM; Heeres A; Dierckx RAJO; Visser TJ; de Vries EFJ; Elsinga PH
    Mol Pharm; 2022 Jul; 19(7):2287-2298. PubMed ID: 35732005
    [No Abstract]   [Full Text] [Related]  

  • 20. Opposing relationships of BMI with BOLD and dopamine D2/3 receptor binding potential in the dorsal striatum.
    Cosgrove KP; Veldhuizen MG; Sandiego CM; Morris ED; Small DM
    Synapse; 2015 Apr; 69(4):195-202. PubMed ID: 25664726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.